Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Glaxosmithkline Plc darapladib phase III solid study results


Tuesday, 13 May 2014 02:00am EDT 

Glaxosmithkline Plc:Announced headline results from its second phase III study with darapladib, SOLID-TIMI 52, evaluating efficacy of its investigational Lp-PLA2 inhibitor in adults following an acute coronary syndrome.In study, darapladib did not achieve primary endpoint of reduction of major coronary events versus placebo when added to standard of care.Overall safety profile for darapladib showed no major safety concerns and was generally consistent with safety data seen in previously reported phase III study, STABILITY.Further analysis of data is ongoing, Darapladib is not approved for use anywhere in world.Acute coronary syndrome is term used to describe situations or events , including heart attack, where there is sudden reduction of blood flow to heart.Initial presentation by patient with acute coronary syndrome results in a diagnosis of coronary heart disease.Primary endpoint measure in SOLID-TIMI 52 study was time to first occurrence of any event from composite of coronary heart disease death, myocardial infarction (heart attack) and urgent coronary revascularisation for myocardial ischemia. 

Company Quote

44.41
0.78 +1.79%
22 Oct 2014